Aspira Women's Health Inc. financial data

Symbol
AWH on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
12117 Bee Caves Road Building Three, Suite 100, Austin, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
VERMILLION, INC. (to 6/10/2020), CIPHERGEN BIOSYSTEMS INC (to 8/17/2007)
Latest financial report
10-Q - Q3 2024 - Nov 19, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 88 % -53.2%
Quick Ratio 4.59 % -15.3%
Debt-to-equity -322 % -155%
Return On Equity 594 %
Return On Assets -267 % -66.2%
Operating Margin -206 % +45.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 16.7M shares
Common Stock, Shares, Outstanding 16.3M shares +58.3%
Entity Public Float 17.7M USD -64.8%
Common Stock, Value, Issued 16K USD +45.5%
Weighted Average Number of Shares Outstanding, Basic 15.4M shares +57.6%
Weighted Average Number of Shares Outstanding, Diluted 15.4M shares +57.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 9.15M USD +11.9%
Revenue from Contract with Customer, Excluding Assessed Tax 2.26M USD +1.8%
Research and Development Expense 3.84M USD -2.96%
Selling and Marketing Expense 7.91M USD -11.7%
General and Administrative Expense 10.4M USD -14.3%
Operating Income (Loss) -17M USD +14.3%
Nonoperating Income (Expense) 2.19M USD
Net Income (Loss) Attributable to Parent -14.8M USD +18.7%
Earnings Per Share, Basic -1.16 USD/shares +43.7%
Earnings Per Share, Diluted -1.16 USD/shares +43.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.13M USD -58.2%
Accounts Receivable, after Allowance for Credit Loss, Current 1.25M USD -21.1%
Inventory, Net 290K USD -3.65%
Other Assets, Current 291K USD
Assets, Current 4.11M USD -45.7%
Property, Plant and Equipment, Net 99K USD -55.2%
Operating Lease, Right-of-Use Asset 515K USD -14.2%
Other Assets, Noncurrent 32K USD +146%
Assets 4.76M USD -45.1%
Accounts Payable, Current 2.55M USD +84.6%
Employee-related Liabilities, Current 90K USD
Accrued Liabilities, Current 2.49M USD -19.3%
Liabilities, Current 5.47M USD +5.89%
Operating Lease, Liability, Noncurrent 387K USD -9.79%
Liabilities 7.28M USD -21.9%
Retained Earnings (Accumulated Deficit) -530M USD -2.87%
Stockholders' Equity Attributable to Parent -2.52M USD -282%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -2.52M USD -282%
Liabilities and Equity 4.76M USD -45.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.6M USD +22.3%
Net Cash Provided by (Used in) Financing Activities 5.27M USD
Net Cash Provided by (Used in) Investing Activities -20K USD -150%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 16.3M shares +58.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 818K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 2.13M USD -60.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6K USD -66.7%
Deferred Tax Assets, Valuation Allowance 57.2M USD +15.1%
Deferred Tax Assets, Gross 57.3M USD +15.3%
Operating Lease, Liability 579K USD -12.9%
Payments to Acquire Property, Plant, and Equipment 20K USD +150%
Lessee, Operating Lease, Liability, to be Paid 642K USD -13.6%
Property, Plant and Equipment, Gross 1.98M USD -37.7%
Operating Lease, Liability, Current 192K USD -18.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 223K USD -0.89%
Lessee, Operating Lease, Liability, to be Paid, Year One 229K USD -6.53%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -12.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63K USD -19.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 84K USD -50.6%
Deferred Tax Assets, Operating Loss Carryforwards 52.5M USD +18%
Unrecognized Tax Benefits 10.7M USD +4.82%
Lessee, Operating Lease, Liability, to be Paid, Year Four 52K USD +189%
Operating Lease, Payments 465K USD +9.16%
Additional Paid in Capital 516M USD +1.44%
Depreciation, Depletion and Amortization 29K USD -58.6%
Deferred Tax Assets, Net of Valuation Allowance 123K USD
Share-based Payment Arrangement, Expense 1.29M USD -9.33%